Dec. 21 at 3:33 AM
Well… phase 2b showed pretty good results that will likely be reflected in phase 3. I see
$RNAC being indicated mainly for biologic-naive gMG (about 70-80% of the TAM), while
$KYTX (an invasive and costly therapy due to hospitalization and chemo) would definitely be used for refractory cases.
Even if
$RNAC captures 5% of the TAM, its fair value would be
$60 per share for a 1.5-2B valuation.
2026 year will be interesting (and probably stock will continue to be dead money for several months as phase 3 readout might be around Oct/Sept - which may push share price to
$20), and then 2027 year will be very fun.
